Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
BACKGROUND: Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. METHODS: All serious adverse events that...
Những tác giả chính: | Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Stanley, A, Stokes, J, Julier, P, Iveson, C, Duvvuri, R, McConkey, C |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2007
|
Những quyển sách tương tự
-
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Bằng: Midgley, R, et al.
Được phát hành: (2010) -
VICTOR: A phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection
Bằng: Kerr, D, et al.
Được phát hành: (2008) -
VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
Bằng: Midgley, R, et al.
Được phát hành: (2008) -
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Bằng: Gray, R, et al.
Được phát hành: (2007) -
Adjuvant therapy of colorectal cancer.
Bằng: Midgley, R, et al.
Được phát hành: (2000)